Core--Xenograft Facility

通过开发和维护几种可连续移植的GBM肿瘤株，其中每一种都已经或将被表征为具有GBM特征的病变，Xenograft Core将为孢子研究人员提供健壮的动物模型，概括人类表型中看到的侵袭性。连续传代的异种移植物提供了比已建立的异种移植细胞系更具临床相关性的模型。这一确定对神经肿瘤学研究有许多影响，但对实验疗法的测试可能是最重要的。我们认为，用连续移植的GBM异种移植物测试抗肿瘤疗法的结果将显示出与人类临床试验结果更好的一致性。 具体地说，Xenograft Core将： 1：启动、传代和存档来自Mayo胶质瘤患者的异种移植瘤。 2：在每种异种移植物建立时提供详细的分子特征，并监测特征的保留。 3：收集、加工和分布在Mayo内外的石蜡包埋的异种肿瘤组织、血清/血浆、DNA、RNA和蛋白质。 4：协调和执行所有体内治疗测试，包括根据需要对颅内异种移植进行核磁共振图像分析，以评估肿瘤对治疗的反应。 5：保持所有异种移植组织和相关生物标本的最新记录。 所有标本将在严格的质量控制下收集和处理，并将分发给孢子研究人员或为未来的孢子研究项目储存。孢子病理学核心将确保标本得到适当的固定、染色和组织学评估。所有活动都将在生物统计核心中使用对孢子至关重要的复杂数据库进行跟踪。该数据库合并了Mayo的活动，并允许与研究项目中收集的临床和其他数据进行集成。

Through the development and maintenance of several serially transplantable GBM tumor lines, each of which has been or will be characterized for GBM signature lesions, the Xenograft Core will provide to SPORE investigators robust animal models that recapitulate the invasiveness seen in the human phenotype. The serially passaged xenografts provide a more clinically relevant model than established cell lines grown as xenografts. This determination has many implications for neuro-oncology research, but is likely to be of greatest importance to the testing of experimental therapeutics. It is our contention that results from testing anti-tumor therapeutics with serially-transplanted GBM xenografts will show improved consistency with clinical trial results in humans. Specifically, the Xenograft Core will: 1: Initiate, passage, and archive xenograft tumors derived from Mayo glioma patients. 2: Provide detailed molecular characterization of each xenograft upon establishment and monitor for retention of characteristics. 3: Collect, process, and distribute within and outside Mayo, paraffin-embedded xenograft tumor tissues, serum/plasma, DNA, RNA, and protein. 4: Coordinate and conduct all in vivo therapeutics testing, including NMR image analysis of intracranial xenografts as needed to assess tumor response to therapy. 5: Maintain up-to-date records on all xenograft tissues and related biospecimens. All specimens will be collected and processed under tight quality control, and will be distributed to SPORE researchers or banked for future SPORE research projects. The SPORE Pathology Core will assure that specimens are properly fixed, stained, and histologically evaluated. All activities will be tracked in the Biostatistics Core using a sophisticated database essential to the SPORE. This database merges the activities at Mayo, and allows integration with clinical and other data collected in research projects.